Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KB801 in Stage 2 or 3 Neurotrophic Keratitis
NCT06999733Phase 2Recruiting
- Sponsor
- Krystal Biotech, Inc.
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of KB801 in neurotrophic keratitis (NK), sponsored by Krystal Biotech, Inc.. Started Jul 2025; status: recruiting.
02
Drugs
KB801
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on NCT06999733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06999733.